The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Official Title: Neoadjuvant Platform Trial in Patients With Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT05714891
Brief Summary: This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?
Detailed Description: The purpose of the pre-study screening is to test for biomarkers. The testing will be done using a sample of your tumor tissue. Each substudy will be looking at what effects a new drug has on the patients and their lung cancer, as well as any side effects of the treatment. The purpose of each substudy is to see if the biomarkers that were identified at screening can be used to determine treatment outcomes, like how the cancer cells respond to treatment and whether the study drug will shrink the tumour before surgery and prevent it from returning after surgery.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cross Cancer Institute, Edmonton, Alberta, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Kingston Health Sciences Centre, Kingston, Ontario, Canada
London Regional Cancer Program, London, Ontario, Canada
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
University Health Network, Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
The Research Institute of the McGill University, Montreal, Quebec, Canada
University Institute of Cardiology and, Quebec City, Quebec, Canada
Name: Jonathan Spicer
Affiliation: McGill University, Montreal, QC Canada
Role: STUDY_CHAIR
Name: Normand Blais
Affiliation: CHUM-Centre Hospitalier de l'Universite de Montreal, QC Canada
Role: STUDY_CHAIR